Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center

Evan Rosenbaum(Memorial Sloan Kettering Cancer Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Ping Chi(Memorial Sloan Kettering Cancer Center), Ahmet Zehir(Natera (United States)), Daniel Kashani(SUNY Downstate Health Sciences University), William D. Tap(Memorial Sloan Kettering Cancer Center), Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Mrinal M. Gounder(Memorial Sloan Kettering Cancer Center), Mark T.A. Donoghue(Memorial Sloan Kettering Cancer Center), Jason E. Chan(Memorial Sloan Kettering Cancer Center), Mark A. Dickson(Memorial Sloan Kettering Cancer Center), Benjamin A. Nacev(University of Pittsburgh), Shaleigh Smith(Memorial Sloan Kettering Cancer Center), Martina Bradić(New York University), Sujana Movva(Memorial Sloan Kettering Cancer Center), Samuel Singer(Memorial Sloan Kettering Cancer Center), Anita S. Bowman(Memorial Sloan Kettering Cancer Center), Ciara M. Kelly(Memorial Sloan Kettering Cancer Center), Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Allison L. Richards(Memorial Sloan Kettering Cancer Center), Mary Lou Keohan(Memorial Sloan Kettering Cancer Center), Viswatej Avutu(Memorial Sloan Kettering Cancer Center)
Journal for ImmunoTherapy of Cancer
April 1, 2022
Cited by 58


Related Papers